Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma

被引：0
作者：
Xiaoying Gu
Su Zhang
Xuejiao Yang
Tao Guan
Zhenyu Hou
Manqing Cao
Huikai Li
Ti Zhang
机构：
[1] Tianjin Medical University Cancer Institute and Hospital,Department of Hepatobiliary Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
[2] National Clinical Research Center for Cancer,Department of Gynecologic Oncology, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
[3] Tianjin Medical University Cancer Institute and Hospital,Present Address: Department of Anesthesiology
[4] National Clinical Research Center for Cancer,Department of Breast Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
[5] The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture,Present Address: Department of Hepatic Surgery
[6] Tianjin Medical University Cancer Institute and Hospital,undefined
[7] National Clinical Research Center for Cancer,undefined
[8] Fudan University Shanghai Cancer Center,undefined
[9] Shanghai Medical College,undefined
[10] Fudan University,undefined
来源：
BMC Gastroenterology | / 22卷
关键词：
Apatinib; Anti-angiogenesis therapy; Adverse Events; Hepatocellular Carcinoma; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 79 条
  • [1] Gordan JD(2020)Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline J Clin Oncol 38 4317-4345
  • [2] Kennedy EB(2021)State-of-the-art surgery for hepatocellular carcinoma Langenbeck's archives of surgery 406 2151-2162
  • [3] Abou-Alfa GK(2015)Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial J Clin Oncol 33 172-179
  • [4] Machairas N(2021)Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel? Hepatobiliary Surg Nutr 10 180-192
  • [5] Tsilimigras DI(2018)Molecular therapies and precision medicine for hepatocellular carcinoma Nature reviews Clinical oncology 15 599-616
  • [6] Pawlik TM(2016)Antiangiogenic therapy in oncology: current status and future directions The Lancet 388 518-529
  • [7] Cainap C(2020)Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study J Clin Oncol 38 4507-4507
  • [8] Qin S(2017)Apatinib is effective for treatment of advanced hepatocellular carcinoma Oncotarget 8 105596-105605
  • [9] Huang WT(2020)Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma Cancer Manag Res 12 3163-3173
  • [10] Zhang T(2013)Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy Drug safety 36 413-426
12345678